ReneSola (NYSE:SOL) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued to investors on Thursday, American Banking News.com reports. ReneSola Ltd. (ADR) (NYSE:SOL) stock opened at $3.29 in last session, and closed at $3.58, while the day range of stock is $3.27 – $3.59. The stock showed a positive weekly performance of 6.23%.
VIVUS, Inc. (NASDAQ:VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental application that proposes to revise the STENDRA™ (avanafil) prescribing information with efficacy and safety information from Study TA-501, entitled “A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with Erectile Dysfunction.” The PDUFA date for the supplemental filing is September 20, 2014. VIVUS, Inc. (NASDAQ:VVUS) stock opened at $6.88, in last session and closed at $7.20, by gaining 5.65 %. The 52 week range of the stock is $6.43 – $15.62. Company’s market capitalization is $732.28 million.
JinkoSolar Holding Co. Ltd (NYSE:JKS) has supplied solar PV modules to CSEM-uae (CSEM), an independent, non-profit Swiss-UAE joint venture company for applied research. The modules will be used for CSEM’s Solar Outdoor Laboratory, an R&D and innovation center for renewable energy in Ras al-Khaimah, UAE. JinkoSolar Holding Co., Ltd. (NYSE:JKS) stock advanced 5.33% and finished the last session at $31.63. The EPS of the stock remained -5.52. Company’s market capitalization is $850.11 million.
Auxilium Pharmaceuticals (NASDAQ:AUXL) had its price objective hosited by RBC Capital from $22.00 to $28.00 in a report released on Monday, Stock Ratings News reports. RBC Capital currently has an outperform rating on the stock. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) stock opened the session at $27.65, and closed the session at $28.30. The 52 week range of the stock remained $13.87 – $28.61 and the day range was $27.42 – $28.61.